[Amineptine and depressive symptoms, cardiovascular and ophthalmological acceptabilities (author's transl)].
Amineptine is a new compound derived from the tricyclic antidepressants whose mechanism of action is mainly dopaminergic. In a clinical open trial, fifty patients suffering from neurotic, reactive and psychotic depression have been treated by 231 mg/day +/- 7 (mean +/- SEM) during 30 days. Results were assessed from Hamilton Rating Scale for depression before treatment and on D7, D14, D30. Cardiovascular and ophthalmological acceptability is discussed.
D000275:Adjustment Disorders / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D002318:Cardiovascular Diseases / Q000139:chemically induced; D003863:Depression / Q000188:drug therapy*; D003866:Depressive Disorder / Q000188:drug therapy*; D003986:Dibenzocycloheptenes / Q000009:adverse effects / Q000627:therapeutic use*; D004562:Electrocardiography; D005128:Eye Diseases / Q000139:chemically induced; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D013997:Time Factors
D003986:Dibenzocycloheptenes; C011597:amineptin
Points d'impact de l'amineptine sur les symptômes de la dépression. Acceptabilité cardio-vasculaire et ophtalmologique.